Therefore, the development of a new combination therapy of ADT plus anti-CCL5/HIF2α/AR signaling may help us to overcome the failure of ADT with better efficacy to suppress PCa cell invasion. The gene discussed is CCL5; the disease is posterior cortical atrophy.